180 related articles for article (PubMed ID: 9650851)
21. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
[TBL] [Abstract][Full Text] [Related]
22. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
Szepeshazi K; Schally AV; Rick FG; Block NL; Vidaurre I; Halmos G; Szalontay L
Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257
[TBL] [Abstract][Full Text] [Related]
23. A potent bombesin receptor antagonist inhibits bombesin-stimulated growth of mouse colon cancer cells in vitro: absence of autocrine effects.
Narayan S; Spindel ER; Rubin NH; Singh P
Cell Growth Differ; 1992 Feb; 3(2):111-8. PubMed ID: 1323998
[TBL] [Abstract][Full Text] [Related]
24. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
25. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
Halmos G; Schally AV
Proc Natl Acad Sci U S A; 1997 Feb; 94(3):956-60. PubMed ID: 9023364
[TBL] [Abstract][Full Text] [Related]
26. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice.
Pinski J; Halmos G; Schally AV
Cancer Lett; 1993 Jul; 71(1-3):189-96. PubMed ID: 8103419
[TBL] [Abstract][Full Text] [Related]
27. In-vivo effect of somatostatin analog, lanreotide, and/or grp antagonist, bim-26226, on the growth of colon-cancer peritoneal carcinomatosis in the rat.
Gouyon B; Reyldesmars F; Leromancer M; Pigeon C; Lewin M; Lehy T
Int J Oncol; 1995 Nov; 7(5):1167-73. PubMed ID: 21552947
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide.
Kiaris H; Schally AV; Sun B; Armatis P; Groot K
Oncogene; 1999 Nov; 18(50):7168-73. PubMed ID: 10597318
[TBL] [Abstract][Full Text] [Related]
29. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
Hong SK; Yang SY; Yin SH; Yang KX
Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
[TBL] [Abstract][Full Text] [Related]
30. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results.
Raderer M; Hamilton G; Kurtaran A; Valencak J; Haberl I; Hoffmann O; Kornek GV; Vorbeck F; Hejna MH; Virgolini I; Scheithauer W
Br J Cancer; 1999 Feb; 79(3-4):535-7. PubMed ID: 10027326
[TBL] [Abstract][Full Text] [Related]
31. Conveyance of partial agonism/antagonism to bombesin/gastrin-releasing peptide analogues on Swiss 3T3 cells by a carboxyl-terminal leucine insertion.
Kull FC; Leban JJ; Landavazo A; Stewart KD; Stockstill B; McDermed JD
J Biol Chem; 1992 Oct; 267(29):21132-8. PubMed ID: 1400423
[TBL] [Abstract][Full Text] [Related]
32. Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity.
Coy DH; Taylor JE; Jiang NY; Kim SH; Wang LH; Huang SC; Moreau JP; Gardner JD; Jensen RT
J Biol Chem; 1989 Sep; 264(25):14691-7. PubMed ID: 2475489
[TBL] [Abstract][Full Text] [Related]
33. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
Rick FG; Buchholz S; Schally AV; Szalontay L; Krishan A; Datz C; Stadlmayr A; Aigner E; Perez R; Seitz S; Block NL; Hohla F
Cell Cycle; 2012 Jul; 11(13):2518-25. PubMed ID: 22751419
[TBL] [Abstract][Full Text] [Related]
34. Gastrin-releasing peptide is a modulatory neurotransmitter of the descending phase of the peristaltic reflex.
Grider JR
Am J Physiol Gastrointest Liver Physiol; 2004 Dec; 287(6):G1109-15. PubMed ID: 15297260
[TBL] [Abstract][Full Text] [Related]
35. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S
J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673
[TBL] [Abstract][Full Text] [Related]
36. GRP-receptor-mediated signal transduction, gene expression and DNA synthesis in the human pancreatic adenocarcinoma cell line HPAF.
Burghardt B; Wenger C; Barabás K; Rácz G; Oláh A; Flautner L; Coy DH; Gress TM; Varga G
Peptides; 2001 Jul; 22(7):1119-28. PubMed ID: 11445243
[TBL] [Abstract][Full Text] [Related]
37. Importance of gastrin-releasing peptide on acid-induced secretin release and pancreaticobiliary and duodenal bicarbonate secretion.
Glad H; Svendsen P; Knuhtsen S; Olsen O; Schaffalitzky de Muckadell OB
Scand J Gastroenterol; 1996 Oct; 31(10):993-1000. PubMed ID: 8898420
[TBL] [Abstract][Full Text] [Related]
38. Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist.
Hildebrand P; Lehmann FS; Ketterer S; Christ AD; Stingelin T; Beltinger J; Gibbons AH; Coy DH; Calam J; Larsen F; Beglinger C
Gut; 2001 Jul; 49(1):23-8. PubMed ID: 11413106
[TBL] [Abstract][Full Text] [Related]
39. Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma.
Kanashiro CA; Schally AV; Cai RZ; Halmos G
Anticancer Drugs; 2005 Feb; 16(2):159-65. PubMed ID: 15655413
[TBL] [Abstract][Full Text] [Related]
40. Gastrin releasing peptide-preferring bombesin receptors mediate growth of human renal cell carcinoma.
Pansky A; DE Weerth A; Fasler-Kan E; Boulay JL; Schulz M; Ketterer S; Selck C; Beglinger C; VON Schrenck T; Hildebrand P
J Am Soc Nephrol; 2000 Aug; 11(8):1409-1418. PubMed ID: 10906154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
